Singapore, Jan. 7 -- Avance Clinical, a full-service Australia headquartered contract research organisation (CRO) focused on accelerating clinical development for biotech sponsors, has announced the acquisition of LumaBridge, a specialised US-based clinical CRO with deep expertise in oncology trials.

This strategic acquisition expands Avance's existing US presence and marks a significant milestone in accelerating the company's growth in oncology, the largest and fastest-growing therapeutic area in global R&D. Both organisations share a commitment to deliver high quality, innovative and efficient oncology clinical trials that accelerate the development of next-generation therapies to patients worldwide.

LumaBridge will form the foundatio...